ZVRA
Zevra Therapeutics Inc
NASDAQ · Pharmaceuticals
$8.60
+0.24 (+2.87%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 29.68M | 31.66M | 114.07M | 109.96M | 97.45M |
| Net Income | -132,649,822 | -127,330,247 | 32.69M | 24.47M | 21.13M |
| EPS | — | — | — | — | — |
| Profit Margin | -446.9% | -424.5% | 28.7% | 22.3% | 21.7% |
| Rev Growth | -6.2% | -6.2% | +11.2% | -4.5% | -6.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 150.02M | 150.02M | 155.99M | 183.66M | 151.32M |
| Total Equity | 100.01M | 100.01M | 397.65M | 340.87M | 348.61M |
| D/E Ratio | 1.50 | 1.50 | 0.39 | 0.54 | 0.43 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -98,761,988 | -100,068,140 | 65.90M | 54.29M | 55.97M |
| Free Cash Flow | — | — | 17.86M | 22.49M | 20.93M |